Considering that GBA mutation leads to a decrease in the activity of glucocerebrosidase, resulting in the accumulation of glucosylceramide, glucosylceramide synthase inhibitors are currently undergoing a clinical trial to treat patients with PD harboring GBA mutations [74]. This evidence concerns the gene GBA1 and Parkinson disease.